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Effectiveness of In-Laboratory
High-Dose Clopidogrel Loading
Versus Routine Pre-Load in Patients
Undergoing Percutaneous Coronary Intervention
Results of the ARMYDA-5 PRELOAD
(Antiplatelet therapy for Reduction of MYocardial Damage
during Angioplasty) Randomized Trial
Germano Di Sciascio, MD,* Giuseppe Patti, MD,* Vincenzo Pasceri, MD,† Laura Gatto, MD,*
Giuseppe Colonna, MD,‡ Antonio Montinaro, MD,‡ on behalf of the ARMYDA-5
PRELOAD Investigators
Rome and Lecce, Italy
Objectives This study sought to evaluate safety and effectiveness of in-laboratory (in-lab) 600-mg clopidogrel loading pre-
percutaneous coronary intervention (PCI) versus routine 6-h pre-load.
Background Clopidogrel pre-treatment significantly improves outcome in patients undergoing PCI; however, efficacy of an in-lab
loading strategy before PCI after coronary angiography versus routine pre-load has not been fully characterized.
Methods A total of 409 patients (39% with acute coronary syndrome) were randomized to receive a 600-mg clopidogrel
loading dose 4 to 8 h before PCI (pre-load group, n  204) or a 600-mg loading dose given in the catheteriza-
tion lab after coronary angiography, but prior to PCI (in-lab group, n  205). Primary end point was 30-day inci-
dence of major adverse cardiac events: cardiac death, myocardial infarction (MI), or unplanned target vessel re-
vascularization.
Results There was no significant difference in primary end point between the 2 randomization arms (8.8% in-lab vs.
10.3% pre-load; p  0.72); this was mainly driven by periprocedural MI (8.8% vs. 9.3%, p  0.99). No increased
risk of bleeding or vascular complications was observed in the pre-load arm (5.4% vs. 7.8%; p  0.42). As deter-
mined by the VerifyNow assay (Accumetrics, San Diego, California), patients in the in-lab group showed higher
platelet reactivity during PCI and 2 h after intervention versus those in the pre-load arm (p  0.043).
Conclusions ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) trial indi-
cates that a strategy of 600-mg in-lab clopidogrel load pre-PCI may have similar clinical outcomes as routine
4- to 8-h pre-load. Thus, when indicated, in-lab clopidogrel administration can be a safe alternative to routine
pre-treatment given before knowing patients’ coronary anatomy. (J Am Coll Cardiol 2010;56:550–7) © 2010
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.067i
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slopidogrel loading before percutaneous coronary interven-
ion (PCI) can significantly improve clinical outcome; re-
ent studies show that a 600-mg clopidogrel load given 2
prior to the procedure achieves better clinical results
ompared to a 300-mg dose (1). Pharmacokinetic evidence
rom the *Department of Cardiovascular Sciences, Campus Bio-Medico University
f Rome, Rome, Italy; †Interventional Cardiology Unit, San Filippo Neri Hospital,
ome, Italy; and ‡Interventional Cardiology Unit, Vito Fazzi Hospital, Lecce, Italy.
he authors have reported that they have no relationships to disclose.s
Manuscript received October 7, 2009; revised manuscript received December 4,
009, accepted January 2, 2010.ndicates that 600-mg clopidogrel achieves maximal platelet
nhibition within 2 h after drug administration, whereas the
onventional 300 mg will require longer than 12 h (2–4).
See page 558
he CREDO (Clopidogrel for the Reduction of Events
uring Observation) trial demonstrated a time dependence
f the clinical benefit with the 300-mg dose utilized in the
tudy, with at least 15 h of pre-treatment required to
ignificantly decrease adverse events (5). Furthermore, data
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August 10, 2010:550–7 In-Lab Clopidogrel Loading Versus Routine Pre-Loadrom the ISAR-REACT (Intracoronary Stenting and An-
ithrombotic Regimen: Rapid Early Action for Coronary
reatment) study (6), which utilized a routine 600-mg clopi-
ogrel loading dose given2 h prior to PCI, indicate that this
pproach abolishes time-dependent differences in 30-day ma-
or adverse cardiac events (MACE) related to pre-treatment
uration (2 to 3 h vs. 3 to 6 h vs. 6 to 12 h vs. 12 h).
Given the common practice of performing PCI at the
ame setting as diagnostic coronary angiography, many
enters routinely pre-load with clopidogrel (at variable
osing) all patients undergoing coronary angiography,
hereas others prefer to complete diagnostic angiography,
ssess the indication for PCI (vs. coronary bypass or medical
herapy), and then administer clopidogrel in the laboratory
efore intervention. However, the former strategy might
ncrease bleeding risk in patients needing urgent surgical
evascularization; direct in-laboratory (in-lab) loading after
iagnostic angiography may help avoid these risks, but it is
nknown whether it would provide adequate antiplatelet
ffect and similar protection from periprocedural ischemic
omplications compared with pre-treatment given several
ours before the procedure.
Thus, the ARMYDA (Antiplatelet therapy for Reduction
f MYocardial Damage during Angioplasty) study group
1,7–11) performed a multicenter, randomized, controlled trial
omparing these 2 treatment options: ARMYDA-5
RELOAD, evaluating safety and effectiveness of a strategy of
00-mg clopidogrel load given in the catheterization laboratory
t the time of PCI after diagnostic coronary angiography versus
outine 600-mg pre-treatment.
ethods
tudy population and design. The design of the study is
llustrated in Figure 1. ARMYDA-5 PRELOAD is a
pontaneous, unfunded clinical trial performed in 3 Italian
nstitutions. Inclusion criteria were clopidogrel-naive pa-
ients with a variety of ischemic coronary syndromes,
ncluding non–ST-segment elevation acute coronary syn-
rome (NSTE-ACS), undergoing coronary angiography.
xclusion criteria were: primary PCI for acute myocardial
nfarction; NSTE-ACS with high-risk features warranting
mergency coronary angiography within 2 h; contraindica-
ions to antithrombotic or antiplatelet therapy (including
latelet count 70  109/l); patients at high risk of
leeding; and treatment with clopidogrel within 10 days
rom randomization. A total of 536 patients fulfilling the
nrollment criteria were randomized to a 600-mg clopi-
ogrel loading dose to be given 4 to 8 h before diagnostic
ardiac catheterization (n  267) or in the catheterization
aboratory at the time of PCI following diagnostic angiog-
aphy (n  269). Eligible patients were assigned to the
llocation arm using an electronic spreadsheet indicating
he group assignment by random numbers; randomiza-
ion blocks were created and distributed to the 3 centers.
fter angiography, 127 patients (24%, 63 in the pre-load arm and 64 in the in-lab arm)
ho did not receive PCI were
xcluded from the study (72
ere treated medically and 55
ith elective coronary artery
ypass surgery [CABG]); thus,
09 patients with significant
oronary disease suitable for percu-
aneous intervention were enrolled
nd represent the study popula-
ion; 204 patients belonged to the
re-load arm and 205 to the
n-lab arm. Study drug adminis-
ration was performed on an
pen-label basis without blind-
ng; by design, PCI was performed immediately after
iagnostic angiography. In patients with ACS, cardiac
atheterization was generally performed within 12 h from
dmission.
Interventions were performed with standard technique, as
reviously described (1,7,10); all patients were pre-treated
ith aspirin (100 mg/day); after PCI, they received aspirin
100 mg/day) indefinitely and were continued on clopi-
ogrel (75 mg/day) for at least 1 month (12 months in those
ith ACS or receiving drug-eluting stents), irrespective of
andomization assignment.
In all patients, blood samples were drawn before and at 8
nd 24 h after the procedure to detect creatine kinase-MB
mass) and troponin-I (mass) levels; further measurements
ere obtained in case of post-procedural symptoms sugges-
ive of myocardial ischemia. Measurements of creatine
inase-MB and troponin-I were performed using the Access 2
mmunochemiluminometric assay (Beckman Coulter, Borea,
alifornia) (12). Upper normal limits were defined as the 99th
ercentile of normal population with a total imprecision of
10%, according to Joint European Society of Cardiology/
merican College of Cardiology guidelines (13). Normal
imits were 3.6 ng/ml for creatine kinase-MB and 0.034
g/ml for troponin-I.
In all patients, platelet reactivity after clopidogrel was
valuated at the time of randomization (baseline value), in
he catheterization laboratory at the time of PCI, and at 2,
, and 24 h after intervention by the VerifyNow P2Y12 assay
Accumetrics, San Diego, California). VerifyNow P2Y12 is
rapid, cartridge-based assay specifically measuring direct
ffects of clopidogrel on the platelet P2Y12 receptor (14);
esults of measurements are expressed as absolute P2Y12
eaction units (PRU) or percentage change of platelet
ggregation from baseline: the lower the PRU value, the
reater the degree of P2Y12 receptor inhibition by clopi-
ogrel, and vice versa. Not included in the Verify Now
nalysis were patients receiving glycoprotein IIb/IIIa inhib-
tors, which interfere with PRU measurement with this
echnique (11,14–16).
One-month clinical follow-up was obtained by office visit in
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass surgery
MACE  major adverse
cardiac events
NSTE  non–ST-segment
elevation
PCI  percutaneous
coronary intervention
PRU  P2Y12 reaction
unitsll study patients. Physicians performing laboratory testing,
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In-Lab Clopidogrel Loading Versus Routine Pre-Load August 10, 2010:550–7ollow-up assessments, and statistical evaluations were not
ware of the randomization assignment. Each patient gave
nformed consent to the study. The study was approved by the
nstitutional review boards of the institutions involved.
nd points. The primary end point of the ARMYDA-5
RELOAD trial was 30-day incidence of MACE (cardiac
eath, myocardial infarction [MI], target vessel revascular-
zation). MI was defined, following the consensus statement
f the Joint European Society of Cardiology/American
ollege of Cardiology Foundation/American Heart Asso-
iation/World Heart Federation Task Force for the Redef-
nition of Myocardial Infarction for clinical trials on coro-
ary intervention (17), as a post-procedural increase of
ardiac biomarkers (troponin or creatine kinase-MB) 3
he 99th percentile of the upper reference limit in patients
ith normal baseline levels of creatine kinase-MB; in
atients with ACS and raised baseline creatine kinase-MB
evels, the definition of a subsequent elevation 50% the
aseline value was applied (18). Target vessel revasculariza-
ion included bypass surgery or repeat PCI of the target
essel(s).
Secondary end points included: 1) any post-procedural
ncrease of markers of myocardial injury (creatine kinase-MB
nd troponin-I) above upper normal limits; 2) occurrence of
ascular/hemorrhagic complications: a) major bleeding, de-
ned as intracranial bleeding or clinically overt bleeding asso-
Figure 1 Design of ARMYDA-5 PRELOAD Trial
CABG  coronary artery bypass grafting; CK-MB  creatine kinase-MB; MI  myoc
elevation acute coronary syndrome; PCI  percutaneous coronary intervention; PRiated with a decrease in hemoglobin of more than 5 g/dl, pccording to the Thrombolysis In Myocardial Infarction
riteria (19); b) minor bleeding (clinically overt hemorrhage
ssociated with a fall in hemoglobin 3 to 5 g/dl); and c)
ntry-site complications (hematoma 5 cm [20], pseudo-
neurysm or arteriovenous fistula); and 3) comparison of
eriprocedural platelet reactivity levels at different time
oints in the 2 arms.
tatistics. For a hypothetical 10% event rate in the pre-
oad group (1,21), a study population of at least 404 patients
202 per treatment arm) would be needed to detect in the
n-lab group a 10.4% absolute increase or a 7.1% reduction
n the incidence of 30-day MACE, with an alpha of 0.05
2-tailed) and beta of 0.8.
Categorical variables are shown as percentages and contin-
ous variables as mean  SD, unless otherwise specified.
ontinuous variables between the 2 arms were compared by t
est for normally distributed values (as assessed by
olmogorov-Smirnov test), otherwise the Mann-Whitney U
est was used. Proportions were compared by Fisher exact test
r chi-square test (Yates corrected) when appropriate. Main
utcome measures are reported with 95% confidence intervals
CIs) of the absolute difference and with odds ratios (ORs)
ith 95% CI, in order to identify the size of possible differences
etween the 2 strategies (in-lab load vs. pre-load). Event-free
urvival analysis was performed by the Kaplan-Meier method
ith log-rank test group comparison. All calculations were
infarction; NSTE-ACS  non–ST-segment
2Y12 reaction units; Rx  treatment; TVR  target vessel revascularization.ardial
U  Performed by SPSS version 15.0 (SPSS Inc., Chicago, Illi-
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August 10, 2010:550–7 In-Lab Clopidogrel Loading Versus Routine Pre-Loadois), and p values 0.05 (2-sided) were considered
ignificant.
esults
tudy population. Main clinical and procedural variables
n the 2 arms are indicated in Tables 1 and 2, respectively.
n the pre-load arm, clopidogrel was given at a mean of
.0 0.6 h before intervention. Age, sex, cardiovascular risk
actors, clinical presentation, left ventricular function, med-
cal therapy at the time of intervention, renal function,
oronary anatomy, and procedural characteristics were sim-
lar in the 2 groups. Of note, diabetes mellitus was present
n 36% of patients in the in-lab arm and in 33% of those in
he pre-load arm, NSTE-ACS in 36% and 43%, respec-
ively, and use of drug-eluting stents in 39% and 35%.
Procedural success was obtained in 202 of 205 patients
99%) of the in-lab group and in 201 of 204 patients (99%)
f the pre-load arm (p  0.69); all unsuccessful procedures
ere due to failure to cross a chronic total occlusion. No
rocedural side branch (2 mm) closure occurred. No
atient died or required emergency CABG surgery.
After diagnostic angiography, 55 patients (n  28 in the
n-lab and n  27 in the pre-load arms) had an indication
or bypass surgery and were excluded from the study; they
nderwent elective surgical revascularization a mean of 10
ays later. In those among them who received pre-load,
here was no CABG-related bleeding.
rimary end point. Incidence of the primary end point was
.8% (18 of 205 patients) in the in-lab arm versus 10.3% (21
Main Clinical FeaturesTable 1 Main Clinical Features
Characteristic
Age, yrs
Male sex
Diabetes mellitus
Systemic hypertension
Hypercholesterolemia
Current smokers
Body mass index, kg/m2
Previous myocardial infarction
Previous coronary intervention
Previous bypass surgery
Clinical pattern
Non–ST-segment elevation acute coronary syndrome
Troponin-positive
Stable angina
Left ventricular ejection fraction, %
Multivessel coronary artery disease
Blood creatinine, mg/dl
Aspirin
Statins
Beta-blockers
ACE inhibitorsValues are given as n (%) or mean  SD.
ACE  angiotensin-converting enzyme.f 204 patients) in the pre-load arm (p 0.72) (Fig. 2). The
n-lab rate was 1.5% better than the pre-load rate; the 95%
I for this difference was from 4.1% worse to 6.9% better,
orresponding to an OR of 0.84 (95% CI: 0.44 to 1.62).
hirty-day occurrence of MACE was mainly due to
eriprocedural myocardial infarction in both arms: 8.8% (18
f 205) versus 9.3% (19 of 204) (p  0.990) (Fig. 3). In the
re-load group, 1 patient had a sudden death 3 weeks after
ntervention, and 1 patient received target vessel revascular-
zation with PCI within 1 month due to subacute bare-
etal stent thrombosis.
A post-hoc subgroup analysis showed no significant
ACE difference in patients with ACS (12 of 73, 16% vs.
of 87, 10%; p 0.36) or multivessel PCI (6 of 32, 19% vs.
of 30, 7%; p  0.26) randomized to in-lab load versus
re-load. In ACS patients, CI for the absolute difference in
ACE was from 16.6% worse to 4% better using in-lab
oading (OR: 1.70, 95% CI: 0.68 to 4.31); for multivessel
CI, OR for in-lab versus pre-load was 3.2 (95% CI: 0.60
o 17.4). In the subgroup with stable angina, MACE
ccurred in 5% (6 of 132) versus 10% (12 of 117; p  0.14)
f patients, with 95% CI of the absolute difference in events
sing in-lab loading ranging from 0.7% worse to 12% better
nd an OR of 0.42 (95% CI: 0.15 to 1.15).
econdary end points. CARDIAC MARKERS ELEVATION.
here was a similar incidence of post-procedural elevation
f creatine kinase-MB above the upper normal limits in the
arms (25% in-lab vs. 28% pre-load; p  0.63); no
ignificant difference was observed in the 2 groups with
dogrel In-Lab Load
(n  205)
Clopidogrel Pre-Load
(n  204) p Value
65 10 66 9 0.29
165 (81) 167 (82) 0.82
74 (36) 67 (33) 0.56
154 (75) 151 (74) 0.89
154 (75) 141 (69) 0.21
44 (22) 42 (21) 0.92
26 3 26.2 2.9 0.49
67 (33) 70 (34) 0.81
65 (32) 49 (24) 0.10
13 (6) 18 (9) 0.45
73 (36) 87 (43) 0.18
34 (47) 39 (45) 0.59
132 (64) 117 (57) 0.18
56 8 55 9 0.22
73 (36) 87 (43) 0.18
1.1 0.8 1.1 0.6 0.90
203 (99) 201 (99) 1
176 (86) 170 (83) 0.57
74 (36) 66 (32) 0.49
144 (70) 152 (75) 0.39Clopi
r
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fter intervention (52% vs. 53%; p  0.80). Distribution of
ardiac markers is indicated in Figure 4.
Figure 2 Primary Study End Point
Thirty-day occurrence of death, myocardial infarction, target vessel revascular-
ization in patients receiving 600-mg clopidogrel in-lab load or pre-load. MACE 
major adverse cardiac events; PCI  percutaneous coronary intervention.
Procedural FeaturesTable 2 Procedural Features
Characteristic
Clopidogre
(n 
Procedural access
Femoral artery 18
Radial artery 20
Vessel treated 2
Left main 4
Left anterior descending 10
Left circumflex 61
Right coronary artery 66
Saphenous vein graft 3
Restenotic lesions 22
Lesion type B2/C 110
Chronic total occlusions (3 months) 15
Multivessel intervention 32
Type of intervention
Balloon only 12
Stent 193
Bifurcations with kissing balloon 12
No. of stents per patient 1.12
Stent diameter, mm 3.14
Total stent length, mm 19
Use of drug-eluting stents 79
Direct stenting 72
No. of pre-dilations 1.6
Stent deployment pressure, atm 14.9
Duration of stent deployment, s 20
Total ischemia 120 s 44
Use of post-dilation 70
Use of glycoprotein IIb/IIIa inhibitors 41
Values are given as n (%) or mean  SD.LEEDING/VASCULAR COMPLICATIONS. No patient had
ost-procedural major bleeding or required transfusions.
inor bleeding was observed in 11 patients (5.4%) of the
0
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In-lab load
Preload
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0.50      0.50      
Figure 3 Individual Components of the Primary End Point
Incidence of adverse events was mainly due to periprocedural myocardial
infarction (MI) in both arms. TVR  target vessel revascularization.
b Load Clopidogrel Pre-Load
(n  204) p Value
184 (90) 0.88
20 (10) 0.88
236
2 (1) 0.69
102 (44) 0.96
60 (25) 0.97
69 (29) 0.81
3 (1) 0.69
21 (10) 0.99
108 (53) 0.96
14 (7) 0.99
30 (15) 0.91
10 (5) 0.84
194 (95) 0.84
11 (5) 0.99
1.14 0.7 0.75
3.15 0.6 0.84
20 9 0.28
71 (35) 0.50
72 (35) 0.95
1.7 1.9 0.60
14.8 2 0.62
22 12 0.08
42 (21) 0.92
69 (34) 0.97
38 (19) 0.82l In-La
205)
5 (90)
(10)
39
(2)
5 (43)
(26)
(28)
(1)
(11)
(54)
(7)
(16)
(6)
(94)
(6)
 0.6
 0.5
10
(39)
(35)
 2
 2.1
 11
(22)
(34)
(20)
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August 10, 2010:550–7 In-Lab Clopidogrel Loading Versus Routine Pre-Loadn-lab arm and in 16 (7.8%) of the pre-load arm (p  0.42)
Fig. 5): in the former group, 1 patient had urethral bleeding
nd 10 a groin hematoma5 cm; in the latter, 1 patient had
rethral and 1 had gum bleeding during glycoprotein
Ib/IIIa infusion, and 14 had a groin hematoma 5 cm.
LATELET REACTIVITY. At study entry, PRU levels were
omparable in both arms; PRU peak was higher at PCI
p  0.043) and at 2 h (p  0.01) in the in-lab arm, and
evels progressively decreased in a parallel fashion in both
rms and became similar at 8 and 24 h (Fig. 6).
iscussion
RMYDA-5 PRELOAD indicates that 600-mg in-lab
oading pre-PCI has similar effects on clinical outcome as a
outine 600-mg pre-load in patients undergoing coronary
ngiography. In particular, loading in the lab after coronary
ngiography is safe, without increase in ischemic complica-
ions, and upstream pre-loading is not associated with
xcess bleeding, which is recognized as a strong predictor of
nfavorable outcome after PCI (22,23).
Both of those concerns have been discussed in previous
tudies addressing the indication of routine pre-loading and
urgical bleeding after clopidogrel administration. The
RAGUE-8 study (24) evaluated pre-loading versus in-lab
trategy in a majority of stable angina patients of whom only
9% underwent PCI, with a trend toward increased minor
leeding, but similar major cardiac events in the pre-load
rm. Conversely, our study population included 40%
STE-ACS, and 80% had PCI after coronary angiography;
hus, unlike PRAGUE-8, the large majority of our enrolled
ohort had a high likelihood of undergoing PCI, and our
esults suggest that bleeding rates are not increased when
re-loading is utilized.
ARMYDA-5 PRELOAD shows no significantly differ-
nt impact on clinical outcome of the 2 strategies; 95% CI
Figure 4 Secondary End Point
Incidence of post-procedural elevation of creatine kinase-MB and
troponin-I 1 to 3 times and 3 times above the upper normal limit.or events using in-lab loading ranged from 4.1% worse to.9% better, indicating that there is confidence that in-lab is
o more than 4.1% higher risk than pre-load.
Is platelet inhibition adequate when an in-lab clopidogrel
olus is given, without several hours pre-loading? No excess
schemic events were observed in the in-lab arm of our
tudy. In particular, concerning stent thrombosis, only 2
ases of subacute stent thrombosis (1 definite  1 probable)
ere observed in the pre-load group and none in the in-lab
roup. When the VerifyNow assay was utilized to evaluate
latelet reactivity, lower PRU values were obtained in the
re-load arm at the time of PCI and at 2 h versus in-lab
oad, but this did not translate into higher event rates in the
n-lab versus the upstream strategy. ARMYDA-PRO (An-
iplatelet Therapy for Reduction of MYocardial Damage
uring Angioplasty–Platelet Reactivity Predicts Outcome)
nd other studies (11,16,25) described the relationship
etween point-of-care measurement of platelet reactivity
nd clinical outcome. The lack of influence on clinical
utcome in ARMYDA-5 PRELOAD may be due both to
he similar baseline PRU values in the 2 groups, and to the
act that PRU at the time of PCI and 2-h after, although
tatistically different in the 2 arms, identify similar risk
roups (as described in ARMYDA-PRO for patients with
RU values in the 4th quartile). Moreover, difference in
RU values at the time of PCI reflects the different timing
f clopidogrel loading in the 2 arms; this difference disap-
ears early after PCI (PRU values in the 2 arms are similar
t 8 h).
In patients who were deemed in need of bypass surgery
fter coronary angiography, those randomized to pre-load
ad no excess surgical bleeding, in accordance with recent
vidence from the ACUITY (Acute Catheterization and
rgent Intervention Triage Strategy) trial (26), suggesting
hat clopidogrel exposure prior to coronary angiography in
CS patients undergoing bypass surgery a mean of 5 days
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Figure 5 Safety Secondary End Point
Bleeding/entry-site complications.
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In-Lab Clopidogrel Loading Versus Routine Pre-Load August 10, 2010:550–7fter may be associated with lower incidence of 30-day
ACE compared with withholding clopidogrel until after
ngiography, without increase in major bleeding risk.
tudy limitations. The study enrolled a mixed patient
opulation, including consecutive patients with both stable
ngina and ACS: subgroup analysis was performed post hoc,
ot as a pre-specified end point. The number of patients in
he ACS subgroup was relatively small, and the confidence
ntervals of the absolute difference in clinical events using
n-lab loading were wide and compatible with an absolute
ncrease up to 16.6% (or a reduction of 4%). Thus, a note of
aution should be considered before concluding that in-lab
lopidogrel administration is adequate in all cases regardless
f clinical presentation.
onclusions
hus, from the ARMYDA-5 PRELOAD trial, we can
onclude the following: 1) neither periprocedural nor
ABG-related bleeding was increased with pre-loading,
onfirming ACUITY data; 2) platelet inhibition is higher in
he pre-load arm, but ischemia protection is still adequate
ith in-lab loading, without evidence of increased throm-
otic risk with high-dose in-lab clopidogrel administration;
) when needed, the latter strategy can be a safe and effective
lternative to pre-treatment given several hours pre-PCI
Figure 6 Periprocedural Platelet Reactivity in the 2 Arms
As measured by the VerifyNow assay, P2Y12 reaction units (PRU) were similar pre-
peak during PCI, and decline gradually at 2, 8, and 24 h. PCI  percutaneous coroefore knowing patients’ anatomy; and 4) accurate patients’isk stratification remains crucial for choosing the appropri-
te loading approach: in low-risk/low PCI probability pa-
ients, routine pre-load may be unnecessary, whereas pa-
ients in whom PCI is planned or likely, especially those
ith ACS (27–29), may safely be treated with early pre-
oading as recommended by guidelines (30). Further studies
ay be needed before the in-lab loading strategy is also
xtended to this high-risk setting of patients.
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